Aurobindo Pharma Share Price Falls 0.62% After USFDA Issues Four Observations at Lannett Company LLC in Seymour, Indiana on August 17-21, 2026
- August 24, 2026
- Posted by: Kunal Singla
- Category: Market
AUROPHARMA: Rs 1,611.20 (0.62%). USFDA: 4 observations at Lannett Company LLC, Seymour IN, Aug 17-21. Company: procedural in nature. Aug 24, 2026.
Quick Answer
Aurobindo Pharma share price fell 0.62% to Rs 1,611.20 on August 24, 2026, after the US Food and Drug Administration inspected Lannett Company LLC, a wholly owned step-down subsidiary in Seymour, Indiana, from August 17 to 21, 2026. The inspection concluded with four observations. Aurobindo Pharma described these as procedural in nature and stated it will respond within the stipulated timeline.
What Is the Aurobindo Pharma USFDA Inspection?
Aurobindo disclosed on August 24, 2026, that the US FDA inspected Lannett Company LLC, its wholly owned step-down subsidiary in Seymour, Indiana, from August 17 to 21, 2026. The inspection concluded with four observations. The company stated: “The inspection concluded with four observations, which are procedural in nature, and we will respond to the US FDA within the stipulated timeline.”
| Parameter | Detail |
|---|---|
| Entity Inspected | Lannett Company LLC, Seymour, Indiana, USA |
| Relationship to Aurobindo | Wholly owned step-down subsidiary |
| Inspection Dates | August 17 to 21, 2026 |
| Number of Observations | Four |
| Nature of Observations | Procedural (per company disclosure) |
| Company Response | Will respond within stipulated timeline |
Click Here – Get Free Investment Predictions
What Do FDA Observations Mean and How Serious Are Procedural Ones?
USFDA Form 483 observations range from minor procedural issues to critical data integrity failures. Aurobindo characterised the four observations at Lannett as procedural in nature, which suggests they relate to documentation or administrative compliance rather than critical quality or safety failures. Procedural observations are common across the pharmaceutical industry and are frequently resolved through updated procedures and training.
If the FDA determines the company’s response is inadequate, it may escalate to a Warning Letter, which is a more serious action. Investors should monitor any follow-up USFDA communication. No Warning Letter has been disclosed for this inspection.
Screen Aurobindo Pharma on Univest Screener
Aurobindo Pharma Share Price Context
Aurobindo Pharma share price was trading at Rs 1,611.20 on August 24, 2026, down 0.62%. The Nifty Pharma index is the broader sector reference. The modest 0.62% decline reflects the market’s reading of the situation as procedural rather than critical. If Aurobindo’s response to the FDA is robust and the observations are resolved without escalation, the stock could recover toward prior levels.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma share price and USFDA updates live.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Aurobindo Pharma share price down today?
Ans. Aurobindo Pharma share price fell 0.62% to Rs 1,611.20 on August 24, 2026, after the US FDA issued four observations following a routine inspection at Lannett Company LLC in Seymour, Indiana. The company has stated the observations are procedural in nature.
What are the four USFDA observations received by Aurobindo?
Ans. The US FDA inspected Lannett Company LLC from August 17 to 21, 2026, and issued four observations. Aurobindo described these as procedural in nature. The company will respond to the FDA within the stipulated timeline.
What is Lannett Company LLC and how is it related to Aurobindo Pharma?
Ans. Lannett Company LLC is a wholly owned step-down subsidiary of Aurobindo Pharma located in Seymour, Indiana, USA. It is part of Aurobindo’s US generics manufacturing and distribution network.
What is Aurobindo Pharma share price today on August 24, 2026?
Ans. Aurobindo Pharma was trading at Rs 1,611.20 on August 24, 2026, down Rs 10.10 or 0.62% from the previous close of Rs 1,621.30.
Are USFDA observations serious for Aurobindo Pharma?
Ans. Aurobindo has characterised the four observations as procedural in nature, which suggests a lower severity level. No Warning Letter has been disclosed. Investors should monitor follow-up FDA communications for any escalation.
Is the Aurobindo USFDA inspection a Warning Letter?
Ans. No. The inspection concluded with four observations, not a Warning Letter. A Warning Letter is a more serious regulatory escalation that has not been disclosed for this inspection.
